Zastosowanie bisfosfonianów u koni

Piśmiennictwo

Soto S., Barbara A.: Bisphosphonates: Pharmacology and Clinical Approach to Their Use in Equine Osteoarticular Diseases. „Journal of Equine Veterinary Science”, 2014, 34, 727-737.Duesterdieck-Zellmer K.: Review of Bisphosphonate Use in Horses. AAEP 62nd Annual Convention Proceedings, 2016, 62, 371-378.Hunter B., Duesterdiek-Zellmer K., Larson M.: Tiludronate concentrations and cytologic findings in synovial fluid after intravenous regional limb perfusion with tiludronate in horses. „Peer J.”, 2015, 3, 889.Drake M., Clarke B., Khosla S.: Bisphosphonates: Mechanism of Action and Role in Clinical Practice. „Mayo Clinic Proceedings”, 2008, 83(9), 1032-1045.Mytnik E. et al.: Molekularny mechanizm działania bisfosfonianów i ich zastosowanie w praktyce klinicznej. „Medycyna Weterynaryjna”, 2010, 66(5), 307-310.FDA Freedom of Information Summary. „NADA”, 141-427, Osphos [online], 2014 [dostęp: 29.05.2017], http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM406997.pdf.Denoix J. et al.: Tiludronate as a New Therapeutic Agent in the Treatment of Navicular Disease: A Double-Blind Placebo-Controlled Clinical Trial. „Equine Veterinary Journal”, 2003, 35(4), 407-413.Gough M., Thibaud D., Smith R.: Tiludronate Infusion in the Treatment of Bone Spavin: A Double Blind Placebo Controlled Trial. „Equine Veterinary Journal”, 2010, 42, 381-387.Coudry V. et al.: Efficacy of Tiludronate in the Treatment of Horses With Signs of Pain Associated With Osteoarthritic Leasions of the Thoracolumbar Vertebral Column. „American Journal of Veterinary Research”, 2007, 68(3), 329-337.Carpenter R.: How to treat dorsal metacarpal disease with regional tiludronate and extracorporeal shock wave therapies in Thoroughbred race horses. AAEP 58th Annual Convention Proceedings, 2012, 58, 546-549.